Early-onset breast cancer cases and recurrences rise in North America and EU; biotech companies develop new treatments.
Early-onset breast cancer cases have risen sharply in North America and the EU, with a surge in patients in remission contracting breast cancer a second time. Despite concerns, optimism remains towards new treatments, with the metastatic HR+/HER2- breast cancer market set to grow by 9.3% CAGR through 2032. Biotech companies, including Oncolytics Biotech Inc., IceCure Medical Ltd, Atossa Therapeutics, Arvinas Inc., and Pfizer Inc, are working on innovative treatments to address the rise in early-onset cancers, particularly breast cancer.
April 30, 2024
3 Articles